ERBB2 and breast carcinoma: Studies have found that compared with other subtypes of breast cancer, such as HER-2 positive breast cancer, TNBC exhibits more immunogenic characteristics, which is mainly reflected in the higher proportion of tumor infiltrating lymphocytes (6), and thus may be a useful marker for tumor immunotherapy.